<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02403687</url>
  </required_header>
  <id_info>
    <org_study_id>1960fp-expr-201501</org_study_id>
    <nct_id>NCT02403687</nct_id>
  </id_info>
  <brief_title>Prospective Analgesic Compound Efficacy (PACE) Study</brief_title>
  <acronym>PACE</acronym>
  <official_title>Prospective Analgesic Compound Efficacy (PACE) Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Express Specialty Pharmacy</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Express Specialty Pharmacy</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A 24-week observational prospective study on the efficacy of topical non-steroidal&#xD;
      anti-inflammatory drugs for the relief of pain.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objectives&#xD;
&#xD;
      The primary objective is the change in pain levels as measured by a 10-point visual analog&#xD;
      scale (VAS). Secondary objectives are changes in concomitant pain medication use, quality of&#xD;
      life, and patient satisfaction with pain management.&#xD;
&#xD;
      Design and Outcomes&#xD;
&#xD;
      The study will be conducted at 1 family practice medical clinic in Houston, TX. Patients will&#xD;
      be prescribed a pain cream compound based on their symptoms and medical history. Periodic&#xD;
      surveys will be administered and concomitant medications recorded to ascertain current pain&#xD;
      levels, quality of life, and satisfaction with current pain levels. Blood tests will be&#xD;
      performed to monitor liver and kidney function.&#xD;
&#xD;
      Interventions and Duration&#xD;
&#xD;
      Non-steroidal anti-inflammatory steroid (NSAID) topical cream will be prescribed to patients&#xD;
      presenting with pain. For patients with localized pain, they will also be prescribed a&#xD;
      transdermal analgesic patch to wear at the site of pain. Subjects will be followed for&#xD;
      24-weeks with surveys administered at baseline, and 1, 2, 4, 8, 12, 16, 20, and 24-weeks&#xD;
      after baseline with blood tests performed at 12 and 24-weeks. If patients do not find&#xD;
      satisfactory pain relief or experience undesirable side effects from the cream they will be&#xD;
      given a prescription for an oral NSAID at anytime during the 24-week observation.&#xD;
&#xD;
      Sample Size and Population&#xD;
&#xD;
      500 patients will be enrolled in the study between March 1, 2015 and March 1, 2017. Subjects&#xD;
      will be screened from the patient population at 1960 Family Practice, 837 Cupress Creek&#xD;
      Parkway, Suite 105, Houston Texas. Subjects will have presented with a primary complaint of&#xD;
      pain. Subjects will be stratified by the following medical indications; Arthritis Muscle&#xD;
      Spasms Tendonitis Idiopathic Gout Synovitis Radiculopathy Migraine&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2015</start_date>
  <completion_date type="Actual">February 2017</completion_date>
  <primary_completion_date type="Actual">December 2016</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>52 Weeks</target_duration>
  <primary_outcome>
    <measure>subjective pain control as measured by a 10-point visual analog scale (VAS).</measure>
    <time_frame>24 weeks</time_frame>
  </primary_outcome>
  <enrollment type="Actual">300</enrollment>
  <condition>Arthritis</condition>
  <condition>Tendonitis</condition>
  <condition>Gout</condition>
  <condition>Radiculopathy</condition>
  <condition>Muscle Spasms</condition>
  <condition>Synovitis</condition>
  <condition>Migraine</condition>
  <condition>Headache</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>baclofen 2%</intervention_name>
    <description>compound topical cream</description>
    <other_name>baclofen</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupivacaine hydrochloride 1%</intervention_name>
    <description>compound topical cream</description>
    <other_name>Bupivacaine hydrochloride</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclobenzaprine hydrochloride 2%</intervention_name>
    <description>compound topical cream</description>
    <other_name>Cyclobenzaprine hydrochloride</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Diclofenac Sodium 3%</intervention_name>
    <description>compound topical cream</description>
    <other_name>Diclofenac Sodium</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Flurbiprofen 10%</intervention_name>
    <description>compound topical cream</description>
    <other_name>Flurbiprofen</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gabapentin 6%</intervention_name>
    <description>compound topical cream</description>
    <other_name>Gabapentin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketamine 10%</intervention_name>
    <description>compound topical cream</description>
    <other_name>Ketamine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lidocaine 2%</intervention_name>
    <description>compound topical cream</description>
    <other_name>Lidocaine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prilocaine 2.5%</intervention_name>
    <description>compound topical cream</description>
    <other_name>Prilocaine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Meloxicam 0.09%</intervention_name>
    <description>compound topical cream</description>
    <other_name>Meloxicam</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sumatriptan 5%</intervention_name>
    <description>compound topical cream</description>
    <other_name>Sumatriptan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tizanidine 0.1%</intervention_name>
    <description>compound topical cream</description>
    <other_name>Tizanidine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Topiramate 2.5%</intervention_name>
    <description>compound topical cream</description>
    <other_name>Topiramate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capsaicin, USP 0.0375%</intervention_name>
    <description>compound topical cream</description>
    <other_name>Capsaicin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Menthol, NF 5.00 %</intervention_name>
    <description>compound topical cream</description>
    <other_name>Menthol</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The patient population will be taken from the patients normally treated at 1960 Family&#xD;
        Practice. Patients not approached for the study will have known medical issues consistent&#xD;
        with the exclusion criteria. Patients who can meet the medical requirements of the&#xD;
        inclusion criteria for the study will be asked to participate. Patients who do not meet the&#xD;
        inclusion criteria, meet any of the exclusion criteria, or decline to be involved in the&#xD;
        study will be treated with traditional standard medical practices, and their standard of&#xD;
        care will not change in any way.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  4.1.1 Primary complaint or clinical findings of arthritis, tendonitis, gout,&#xD;
             synovitis, radiculopathy, muscle spasms, migraines, and/or idiopathic pain.&#xD;
&#xD;
        4.1.2 No new pain medications of any kind in the last 4 weeks. 4.1.3 Between the ages of&#xD;
        18-85yrs.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  4.2.1 Current or history of disease or disorders of the liver, kidneys,&#xD;
             gastrointestinal system, or cardiovascular system.&#xD;
&#xD;
        4.2.2 Blood test indicating kidney, liver, or cardiovascular function outside of normal&#xD;
        clinically accepted ranges. Blood test must be performed in the last 7 days.&#xD;
&#xD;
        4.2.3 Broken or inflamed skin, burns, open wounds, atopic dermatitis or eczema in the area&#xD;
        of pain where the compound cream and transdermal patch would be applied.&#xD;
&#xD;
        4.2.4 Women who are pregnant, nursing, or planning to become pregnant in the next 52-weeks.&#xD;
&#xD;
        4.2.5 Allergy/sensitivity to study drugs or their formulations. 4.2.6 Active drug or&#xD;
        alcohol use or dependence that, in the opinion of the site investigator, would interfere&#xD;
        with adherence to study requirements.&#xD;
&#xD;
        4.2.7 Serious illness (requiring systemic treatment and/or hospitalization) until subject&#xD;
        either completes therapy or is clinically stable on therapy, in the opinion of the site&#xD;
        investigator, for at least 14 days prior to study entry.&#xD;
&#xD;
        4.2.8 Inability or unwillingness of subject to give written informed consent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kate McLellan, PhD</last_name>
    <role>Study Director</role>
    <affiliation>KM Clinical, Inc.</affiliation>
  </overall_official>
  <verification_date>January 2018</verification_date>
  <study_first_submitted>March 5, 2015</study_first_submitted>
  <study_first_submitted_qc>March 30, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 31, 2015</study_first_posted>
  <last_update_submitted>January 30, 2018</last_update_submitted>
  <last_update_submitted_qc>January 30, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 1, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Express Specialty Pharmacy</investigator_affiliation>
    <investigator_full_name>Kate McLellan</investigator_full_name>
    <investigator_title>Study Director</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tendinopathy</mesh_term>
    <mesh_term>Synovitis</mesh_term>
    <mesh_term>Radiculopathy</mesh_term>
    <mesh_term>Spasm</mesh_term>
    <mesh_term>Headache</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Topiramate</mesh_term>
    <mesh_term>Diclofenac</mesh_term>
    <mesh_term>Meloxicam</mesh_term>
    <mesh_term>Flurbiprofen</mesh_term>
    <mesh_term>Lidocaine</mesh_term>
    <mesh_term>Clonidine</mesh_term>
    <mesh_term>Sumatriptan</mesh_term>
    <mesh_term>Ketamine</mesh_term>
    <mesh_term>Gabapentin</mesh_term>
    <mesh_term>Amitriptyline</mesh_term>
    <mesh_term>Tizanidine</mesh_term>
    <mesh_term>Bupivacaine</mesh_term>
    <mesh_term>Prilocaine</mesh_term>
    <mesh_term>Cyclobenzaprine</mesh_term>
    <mesh_term>Baclofen</mesh_term>
    <mesh_term>Capsaicin</mesh_term>
    <mesh_term>Menthol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

